TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01860833
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: time of treatment 14 days
Study: NCT01860833
Drug: Diclofenac
Normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: time of treatment 14 days
Study: NCT01069094
Drug: Progenta
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5 mg, administered as a once daily oral dose for 90 days.
Study: NCT01069094
Drug: Progenta
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg, administered as a once daily oral dose for 90 days.
Study: NCT01069094
Drug: Progenta
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg, administered as a once daily oral dose for 90 days.
Study: NCT01069094
Drug: Lucron Depot
Normalized name: Primoteston Depot
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.75 mg IM monthly
Study: NCT01069094
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as a once daily oral dose for 90 days.
Study: NCT02050828
Drug: AKB-9778
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02652546
Drug: Effect of drug on viral load
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evaluate the effect of CC-11050 on plasma HIV-1 RNA levels by both conventional and single copy assay at week 12 and over all evaluable time points
Study: NCT02652546
Drug: Effect of drug on inflammatory biomarkers
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evaluate the effect of CC-11050 on markers of markers of systemic inflammation (TNF, IL-\^, CRP, IFNg, sCD14, D-dimer) at week 12 and over all evaluable time points.
Study: NCT02958085
Drug: NNC0174-0833
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doses of NNC0174-0833, dosed either once daily or once weekly
Study: NCT02958085
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosed either once daily or once weekly
Study: NCT00740584
Drug: 3% SPL7013 Gel (VivaGel)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single application of VivaGel applied to the vagina on five separate occasions, each occasion separated by a minimum of 5 days.
Study: NCT00012207
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03513276
Drug: Adrenaline 10mcg/ml
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02443155
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered s.c (subcutaneously) or i.v ( intravenously). Subjects will continue their pre-trial insulin treatment
Study: NCT02220530
Drug: Conscious sedation with iv midazolam and fentanyl.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sedation group: Conscious sedation with iv midazolam and fentanyl dosed according to age, weight and baseline conditions of the patients.
Study: NCT01807611
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV.
Study: NCT01376388
Drug: GSK573719/GW642444 Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK573719/GW642444 inhalation powder inhaled orally once daily for 52 weeks.
Study: NCT02870153
Drug: XELOX
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxaliplatin 130mg/m2 IV on D1 every 21 days and Capecitabine 2000mg/m2/day PO, divided by two on D1-14 every 21 days
Study: NCT02754011
Drug: Combination of ribociclib + capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: RIBOCICLIB from 200 to 600mg once daily + CAPECITABINE from 750 to 1000 mg/m² BID, cycles are defined in 21-day periods, 2 weeks on treatment, 1 week off treatment
Study: NCT01060722
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single subcutaneous dose of placebo material
Study: NCT02779530
Drug: Diclofenac
Normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 50 mg po, b.i.d for 6 days
Study: NCT03537651
Drug: TEZ/IVA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination tablet for oral administration.
Study: NCT04104607
Drug: CC-1, PSMAxCD3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of CC-1 over 24 hours for 7 days with possible intra-patient dose-escalation
Study: NCT04354662
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2600 mg/m², d1
Study: NCT04354662
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 200 mg/m², d1
Study: NCT00249912
Drug: Lapaquistat acetate and rosuvastatin
Normalized name: rosuvastatin and ezetimibe
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lapaquistat acetate 50 mg, tablets, orally, once daily and stable Rosuvastatin therapy (10 or 20 mg) for up to 24 weeks.
Study: NCT00249912
Drug: Lapaquistat acetate and rosuvastatin
Normalized name: rosuvastatin and ezetimibe
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lapaquistat acetate 100 mg, tablets, orally, once daily and stable Rosuvastatin therapy (10 or 20 mg) for up to 24 weeks.
Study: NCT00249912
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lapaquistat acetate placebo-matching tablets, orally, once daily and stable Rosuvastatin therapy (10 or 20 mg) for up to 24 weeks.
Study: NCT02396706
Drug: Ivy Leaves Cough Liquid
Normalized name: digitalis leaves
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02396706
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02425969
Drug: Optimal Medical Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal Medical therapy consists of secondary prevention which will include high dose statin and aspirin as well as anti-anginal therapy according to ESC 2013 international treatment guidelines for stable angina as follows; B-Blocker or Calcium channel blocker as first line agents and Nicorandil or Nitrates or Ranolazine as second line treatment titrated against symptoms to maximum tolerated dose. ACE inhibitors or Angiotensin Receptor Blockers will be prescribed if patients also have a diagnosis of hypertension, LVEF ≤40%, diabetes or CKD where appropriate.
Study: NCT00828230
Drug: Placebo foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: One application of placebo foam once daily for 8 weeks
Study: NCT04577378
Drug: Drug: Isotretinoin(Aerosolized 13 cis retinoic acid) plus Aerosolized Itraconazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: After randomization, erosolized 13 cis retinoic acid in gradual one dose increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days plus Aerosolized Itraconazole 5mg per day for 14 days
Study: NCT04577378
Drug: Drug: Isotretinoin(Aerosolized 13 cis retinoic acid)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Aerosolized 13 cis retinoic acid in gradual one dose increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days
Study: NCT01749878
Drug: REGN1500
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01749878
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03896321
Drug: Antiplatelet Agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: effect of dual antiplatelet in management of coronary artery ectasia
Study: NCT03896321
Drug: Anticoagulants
Normalized name: ANTICOAGULANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: effect of oral anticoagulants in management of coronary artery ectasia
Study: NCT00879047
Drug: Alcohol placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid alcohol spritzed on top of juice beverage immediately prior to administration in order to give smell of alcohol, administered once at baseline and again at either 2 or 3 weeks
Study: NCT02208505
Drug: Dexmedetomidine + Remifentanil-low dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose administration (0.5mcg/kg) 10 min before end of the surgery with maintain the infusion of remifentanil (TCI 1 ng/ml) until end of surgery
Study: NCT02208505
Drug: Remifentanil-high dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: maintain the infusion of remifentanil until end of the surgery (TCI 2 ng/ml)
Study: NCT03121963
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: acetaminophen tablet
Study: NCT03121963
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: celecoxib tablet
Study: NCT00095004
Drug: Comparator: placebo / Duration of Treatment: 1 day
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00639015
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Titrated norepinephrine to maintain mean arterial pressure between 65-75 mmHg over a period of 12 hours from the onset of septic shock.
Study: NCT01367561
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02165605
Drug: HylaCare
Approvals — FDA: no, EMA: no, PMDA: no
Description: cream
Study: NCT02165605
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT04655118
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match TL-895
Study: NCT03068468
Drug: BIIB092
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIIB092 intravenous infusion on specified days
Study: NCT01035671
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 28 days of placebo oral capsules. Treatment taken twice daily with meals.
Study: NCT03068468
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo intravenous infusion on specified days
Study: NCT02217683
Drug: Nitric Oxide
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitric oxide at 80 part per million will be administrated by inhalation for approximately 1 hour during the blood transfusion
Study: NCT00799903
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered in addition to standard therapy
Study: NCT01926002
Drug: High-Dose MK-8351
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-Dose MK-8351 administered as a single inhaled dose.
Study: NCT01926002
Drug: Placebo to MK-8351
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-Dose Matching placebo to high-dose or low-dose MK-8351.
Study: NCT03126084
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg of intravenous acetaminophen will be administered twice a day
Study: NCT00328523
Drug: Duration of Treatment: 3 months
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02067936
Drug: Group A propofol + remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Predicted TOL90% according to Bouillon model
Study: NCT02067936
Drug: Group B propofol + remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: TOL 90% according to the Bouillon interaction model
Study: NCT02067936
Drug: Group C propofol + remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: TOL 90% according to the Bouillon interaction model
Study: NCT02067936
Drug: group D propofol + remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: TOL 90% according to the Bouillon interaction model
Study: NCT01510912
Drug: Diclofenac
Normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 35 mg bid or tid Capsules
Study: NCT05307614
Drug: Moksi® 400mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of Moxifloxacin 400 mg Tablet was administered after a 10-hour overnight fast.
Study: NCT05307614
Drug: Drug: Avelox® 400Mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of Moxifloxacin 400 mg Tablet was administered after a 10-hour overnight fast.
Study: NCT00202358
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00652301
Drug: simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: simvastatin 20 mg tablet. Duration of Treatment 31 Weeks.
Study: NCT03710642
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule matched to appearance of active drug.
Study: NCT00034294
Drug: GT160-246
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03030118
Drug: Placebo Oral Capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: An oral capsule placebo is made to match the active intervention medication hydroxychloroquine.
Study: NCT01648972
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02219672
Drug: Triplitode
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Triptolide Triptolide Wilfordii is a Chinese old herb which is widely used as a remedy for rheumatic diseases and nephropathy in China. It is approved that it can play a role as an immune modular.~Other Name: Tripterygium Wilfordii Hook F (TwHF) Drug: cART Participants who will be enrolled in this Triplitode group would be treated with Tenofovir plus lamivudine plus Lopinavir / ritonavir plus raltegravir .
Study: NCT01090024
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching BI 671800
Study: NCT04328441
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracutaneously 0.1ml NaCl 0,9%
Study: NCT03733132
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment of identical tablets to metformin group
Study: NCT04385186
Drug: Support treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day 0: Start of support treatment selected by medical staff according to each each institutional protocol
Study: NCT00149630
Drug: Disulfiram
Normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Disulfiram 250 mg/day by mouth daily during study weeks 2-13. Disulfiram discontinued during study weeks 14-15.
Study: NCT01587040
Drug: SAR245408
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: capsule or tablet Route of administration: oral
Study: NCT01587040
Drug: SAR245409
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: capsule or tablet Route of administration: oral
Study: NCT01564563
Drug: standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment of bleeding
Study: NCT02857491
Drug: sham
Normalized name: SHAMPOO
Approvals — FDA: no, EMA: no, PMDA: no
Description: sham intravitreal injection before vitrectomy
Study: NCT01365403
Drug: RO4917838
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose, Day 1 of study period 1 and Day 16 of study period 2
Study: NCT01564563
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02184325
Drug: Kiddi® Pharmaton Fizz, effervescent tablets
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02184325
Drug: Kiddi® Pharmaton Fizz, effervescent tablets: marketed formula
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02184325
Drug: Comparator product
Approvals — FDA: no, EMA: no, PMDA: no
Description: active substances: Vitamin A, Vitamin B1, Vitamin B2, Vitamin B5, Vitamin B6, Vitamin B12, Vitamin C, Vitamin D, Vitamin E, Manganese, Copper, Calcium, Magnesium, Phosphorous, Iron, Zinc, Sodium, Molybden
Study: NCT00611767
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A 2-day test design involving 2 conditions: saline (Placebo) or Thiopental 1.5mg/kg (loading) with a subsequent infusion rate of 40 mcg/kg/minute (60 minute infusion).
Study: NCT03862833
Drug: Zoledronic Acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 4 mg at day +15 post graft
Study: NCT00801216
Drug: High-dose sequential chemotherapy and autologous transplant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two courses of methotrexate 3.5 g/mq day 1 and cytarabine 2 g/mq twice a day, for two days, Rituximab 375 mg/mq days 3 \& 11 and Intrathecal liposomal cytarabine 50 mg day 6(Phase I) followed in case of response by cyclophosphamide 7 g/mq plus Rituximab 375 mg/mq and Intrathecal liposomal cytarabine 50 mg Leukapheresis A and cryopreservation (Phase II), Cytarabine 2 g/mq twice a day for 4 days, Rituximab 375 mg/m2 and Reinfusion of stem cells (Phase III), etoposide 2 g/mq, Intrathecal liposomal cytarabine 50 mg (Phase IV) and high-dose Thiotepa-BCNU supported by autologous stem cell transplant (Phase V), and whole-brain radiotherapy in patients who do not achieve a complete remission after chemotherapy (Phase VI)
Study: NCT00141622
Drug: Slow sodium
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00722215
Drug: 0.9 % saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 15ml 0.9% saline infused for 15 mins as placebo control
Study: NCT03400475
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One topical application in peri-implant gingival crevice
Study: NCT00108771
Drug: ZR-02-01 Fentanyl Transdermal Matrix Patch
Normalized name: fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Study patches were replaced every 72 hours and were to be applied on the upper chest or lateral aspect of the upper arms. The patch application sites were to be rotated so the patch was not applied to the same skin site for successive applications. Patients were supplied with Tegaderm if needed to keep the patches adhered during the 72 hour wear period.
Study: NCT00108771
Drug: Placebo Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study patches were replaced every 72 hours and were to be applied on the upper chest or lateral aspect of the upper arms. The patch application sites were to be rotated so the patch was not applied to the same skin site for successive applications. Patients were supplied with Tegaderm if needed to keep the patches adhered during the 72 hour wear period
Study: NCT01072357
Drug: Avastin® (bevacizumab)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One time subconjunctival injection of 0.1 mL (2.5 mg) bevacizumab followed by topical treatment with 1% solution bevacizumab four times a day for four weeks.
Study: NCT02390258
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00809055
Drug: Caffeine citrate
Normalized name: Caffeine Citrate
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine to be administered as outlined to compare efficacy of different dosages.
Study: NCT04246541
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive IV ketorolac during surgery followed by 3 days of oral ketorolac (10 mg every 6 hours) for pain control. Patients will also be given oxycodone-acetaminophen (5mg-325mg) PRN for pain not controlled with ketorolac.
Study: NCT04246541
Drug: Oxycodone-Acetaminophen
Normalized name: acetaminophen / oxycodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be discharged with oxycodone-acetaminophen (5mg-325mg) PRN for pain control after surgery.
Study: NCT01493934
Drug: injection of 6-DIG
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unique injection dose of 92.5 MBq
Study: NCT02078089
Drug: Oxcarbazepine
Normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Can be taken with or without food at the same time as morphine. Morphine will be provided to patients free of charge.
Study: NCT02001506
Drug: FEC3-D3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluorouracil 500 mg/m2, every 3 weeks Epirubicin 100 mg/m2, every 3 weeks Cyclophosphamide 500, every 3 weeks~Docetaxel 75 mg/m2, every 3 weeks
Study: NCT00434187
Drug: ERB-041
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02400151
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients randomized to this group will receive placebo for 90 days.
Study: NCT02162420
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 50 mg/kg IV over 2 hours on day -7 from transplant.
Study: NCT03915470
Drug: XF-73
Normalized name: Exeporfinium chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: XF-73 is a dicationic porphyrin derivative having potent bactericidal properties with a novel mode of action.
Study: NCT01233050
Drug: 2% Chlorhexidine Gluconate/70% Isopropyl Alcohol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative skin antisepsis preparation
Study: NCT04168619
Drug: Discontinue methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: According to the international guideline, patients with Roenigk grade 3a which indicate methotrexate-induced liver injury may continue methotrexate with a repeat biopsy in 6 months. In patients with Roenigk grades 3b or 4, indicate significant liver fibrosis/cirrhosis, methotrexate should be discontinued.
Study: NCT03915470
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match XF-73 nasal gel for colour and viscosity.
Study: NCT03160898
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet
Study: NCT00078247
Drug: Tuberculosis treatment
Normalized name: Hydrazides for tuberculosis treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tuberculosis treatment
Study: NCT04179604
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in the placebo group will receive a water-soluble vitamin B2 concentrate with 0.4 mg / ml sodium riboflavin phosphate to obtain the same color as the preparation of levosimendan and ethanol anhydrous 100 mg / ml to resemble the levosimendan odor, which will be administered at the same levosimendan infusion rate.
Study: NCT00920686
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered as 3 placebo hard gelatin capsules
Study: NCT04599972
Drug: CSF-1
Normalized name: CSF-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: One drop bilaterally twice daily for approximately 2 weeks.
Study: NCT04599972
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: One drop bilaterally twice daily for approximately 2 weeks.
Study: NCT03014830
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injections SQ every 2 weeks